The addition of the tyrosine kinase inhibitor tucatinib (Tukysa) to trastuzumab (Herceptin) and capecitabine continued to improve overall survival (OS) and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer, according to updated results from the pivotal HER2CLIMB trial. Read More ›

CDK4/6 inhibitors combined with anti-HER2 agents in HER2-low expressing MBC cases warrant prospective evaluations. Read More ›

Evidence from studies indicates that common genetic and epigenetic features of male and female breast cancer are not shared, but further studies are warranted. Read More ›

Breast cancer survivors should be closely monitored and offered appropriate evidence-based treatment for fatigue, cognitive dysfunction, and sexual problems. Read More ›

An analysis of racial minority groups treated for breast cancer demonstrates worse survival outcomes. Read More ›

Breast cancer’s initiation, progression, and behavior may be affected by chronic inflammation. Read More ›

A significant increase in clinical trial accruals resulted from dedicating a single employee to screening patients, suggesting a potential paradigm for limited resource settings. Read More ›

To reduce cancer-related cognitive impairment, there may be a benefit to targeting specific inflammatory processes. Read More ›

Quality of social support may impact patients’ disease understanding and should be considered when creating clinical interventions. Read More ›

Differences in patient characteristics, CDK4/6 inhibitor schedule, treatment duration, and discontinuation rates may contribute to differences in outcomes. Read More ›